Blogs

Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis

By Aesthetic Multispecialty Society posted Jun 04, 2020 02:30 PM

  
.
0 comments
0 views

Permalink